Podcast episode 26 (in German)

SS-31: The FDA-approved mitochondrial peptide – fact-checked

July 4, 2026

A peptide from the biohacking scene has made it to approval: SS-31, also elamipretide, was approved by the FDA in September 2025 as the first therapy for a mitochondrial disease ever. What that means for healthy aging is another question.

What it is about

Mitochondria, the power plants of the cell, produce the energy carrier ATP on a heavily folded inner membrane. Its folds, the cristae, are held in shape by a special fat: cardiolipin. If it is damaged, energy production collapses and more aggressive oxygen radicals are formed. SS-31 travels specifically into the mitochondrion, attaches to cardiolipin and stabilizes it, a repair of the structure rather than more fuel, as NAD is supposed to provide. The episode explains this mechanism, the approval for the rare Barth syndrome and the mixed results in heart failure. The conclusion is the scientifically strongest peptide in the series, whose approval, however, does not cover what biohackers take it for.

Key points

In September 2025, the FDA approved elamipretide under the name Forzinity for Barth syndrome, a congenital disease in which cardiolipin is disturbed from birth.
In the decisive TAZPOWER trial, muscle strength and walking distance improved measurably on elamipretide; those affected have weak hearts and muscles from early childhood.
In large trials on heart failure, interesting signals appeared in individual cardiac measurements, but the primary endpoints of the trials were missed.
In animal models, SS-31 had a protective effect in nerve damage, in reperfusion damage after a heart attack and in muscle wasting; in humans this is not proven.
The amounts reported in the scene are roughly a factor of 80 below the dose from the trials and the approved medicine; nobody knows whether the effect carries over.
In the trials, SS-31 was considered fairly well tolerated, most likely with reactions at the injection site; unlike many scene substances, there are safety data from controlled trials here.
Declining mitochondria are considered one of the core drivers of aging; tissues with high energy demand such as the heart, muscle and brain are hit first.

Where the data stop

The approval is real, but applies only to a rare disease in a specific group. It says nothing about whether SS-31 helps healthy people with aging; there are no clean studies on this, and in heart failure the clear breakthrough is missing. The idea of combining SS-31 with NAD precursors is a nice theory from the community, not evidence.

Then there is the dose gap: if the trial dose is necessary, the scene amount may remain ineffective; if less is enough, that is not proven. Loose SS-31 is not approved as a medicine in Germany, as of July 2026. Vials from the internet are not pharmaceutically tested; purity and actual amount remain open without a test. Anyone considering intervening in the cell’s power plants should clarify this with a physician.

Listen (in German)

Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music

Published on July 4, 2026.

The topic in the database

A mitochondria-targeted peptide that binds to cardiolipin and stabilizes the energy power plants – and one of the few with real clinical ex…SS-31 (Elamipretide)

All episodes in the app (German)

Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.